Who should a woman talk to when considering surgery to reduce her risk of breast cancer?
The decision to have any surgery to reduce the risk of breast cancer is a major one. A woman who is at high risk of breast cancer may wish to get a second opinion on risk-reducing surgery as well as on alternatives to surgery. For more information on getting a second opinion, see the section “How can I get another doctor’s opinion about the diagnosis and treatment plan” in the NCI fact sheet How to Find a Doctor or Treatment Facility if You Have Cancer.
A woman who is considering prophylactic mastectomy may also want to talk with a surgeon who specializes in breast reconstruction. Other health care professionals, including a breast health specialist, medical social worker, or cancer clinical psychologist or psychiatrist, can also help a woman consider her options for reducing her risk of breast cancer.
Many factors beyond the risk of disease itself may influence a woman’s decision about whether to undergo risk-reducing surgery. For example, for women who have been diagnosed with cancer in one breast, these factors can include distress about the possibility of having to go through cancer treatment a second time and the worry and inconvenience associated with long-term breast surveillance (29). For this reason, women who are considering risk-reducing surgery may want to talk with other women who have considered or had the procedure. Support groups can help connect women with others who have had similar cancer experiences. The searchable NCI database National Organizations That Offer Cancer-Related Services has listings for many support groups.
Finally, if a woman has a strong family history of breast cancer, ovarian cancer, or both, she and other members of her family may want to obtain genetic counseling services. A genetic counselor or other healthcare provider trained in genetics can review the family’s risks of disease and help family members obtain genetic testing for mutations in cancer-predisposing genes, if appropriate.
Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Journal of Clinical Oncology 2006; 24(28):4642-4660.
Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New England Journal of Medicine 1999; 340(2):77-84.
Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304(9):967–975.
Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. Journal of Clinical Oncology 2004; 22(6):1055-1062.
Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine 2001; 345(3):159-164.
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology 2007; 25(11):1329–1333.
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. American Journal of Human Genetics 2003; 72(5):1117–1130.
Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA 2010; 304(24):2724-2731.
Hobert JA, Eng C. PTEN hamartoma tumor syndrome: An overview. Genetics in Medicine 2009; 11(10):687-694.
Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clinical Cancer Research 2012; 18(2):400-407.
Masciari S, Dillon DA, Rath M, et al. Breast cancer phenotype in women with TP53 germline mutations: A Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment 2012; 133(3):1125-1130.
De Bruin ML, Sparidans J, van’t Veer MB, et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: Lower risk after smaller radiation volumes. Journal of Clinical Oncology 2009; 27(26):4239-4246.
Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database of Systematic Revviews 2010; (11):Cd002748.
King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. Journal of Clinical Oncology 2011; 29(16):2158-2164.
Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncology 2010; 11(12):1135–1141.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472):1687–1717.
Singletary S. Techniques in surgery: therapeutic and prophylactic mastectomy. In: Harris J, Lippman M, Morrow M, Osborn C, eds. Diseases of the Breast. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004.
Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: A prospective 1-year follow-up study. Journal of Clinical Oncology 2008; 26(24):3943-3949.
Frost MH, Hoskin TL, Hartmann LC, et al. Contralateral prophylactic mastectomy: Long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Annals of Surgical Oncology 2011; 18(11):3110-3116.
Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. Journal of Clinical Oncology 2005; 23(31):7804-7810.
Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281(23):2189-2197.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 2005; 97(22):1652-1662.
Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P–2 trial. JAMA 2006; 295(23):2727–2741.
Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prevention Research 2010; 3(6):696-706.
Moyer VA, From the U.S. Preventive Services Task Force R, Maryland. Medications for risk reduction of primary breast cancer in women: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 2013. First published online 24 September 24, 2013. doi:10.7326/0003-4819-159-10-201311190-00718 Exit Disclaimer.
Goss PE, Ingle JN, Alés-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine 2011; 364(25):2381–2391.
Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: A Cancer Journal for Clinicians 2007; 57(2):75-89.
Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology 2013; 31(25):3091-3099.
Khan SA. Contralateral prophylactic mastectomy: What do we know and what do our patients know? Exit Disclaimer Journal of Clinical Oncology 2011; 29(16):2132-2135.
Source: National Cancer Institute